High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
(2013)
Journal Article
Liberante, F. G., Pellagatti, A., Boncheva, V., Bowen, D. T., Mills, K. I., Boultwood, J., & Guinn, B. A. (2013). High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British journal of haematology, 162(2), 282-285. https://doi.org/10.1111/bjh.12352
All Outputs (45)
New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer (2013)
Journal Article
Boncheva, V., Bonney, S. A., Brooks, S. E., Tangney, M., O'Sullivan, G., Mirnezami, A., & Guinn, B. A. (2013). New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer. Cancer Gene Therapy, 20(3), 157-168. https://doi.org/10.1038/cgt.2013.5Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both men and women, posing a serious demographic and economic burden worldwide. In the United Kingdom, CRC affects 1 in every 20 people and it is often detected once well establ... Read More about New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer.
Innovative evolution of cancer gene and cellular therapies (2013)
Journal Article
Lam, P., Khan, G., Stripecke, R., Hui, K. M., Kasahara, N., Peng, K. W., & Guinn, B. A. (2013). Innovative evolution of cancer gene and cellular therapies. Cancer Gene Therapy, 20(3), 141-149. https://doi.org/10.1038/cgt.2012.93We provide an overview of the latest developments in cancer gene therapy - from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emerg... Read More about Innovative evolution of cancer gene and cellular therapies.
Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma (2011)
Journal Article
Guinn, B. A., Bosslet, K., Lee, C., Richardson, D., & Orchard, K. (2011). Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma. European Journal of Haematology, 87(6), 554-555. https://doi.org/10.1111/j.1600-0609.2011.01698.x
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia (2011)
Journal Article
Smits, E. L., Lee, C., Hardwick, N., Brooks, S., Van Tendeloo, V. F., Orchard, K., & Guinn, B. A. (2011). Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 60(6), 757-769. https://doi.org/10.1007/s00262-011-1022-6Immunotherapy is currently under active investigation as an adjuvant therapy to improve the overall survival of patients with acute myeloid leukaemia (AML) by eliminating residual leukaemic cells following standard therapy. The graft-versus-leukaemia... Read More about Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.